SEC Form 4 · accession 0001140361-16-070360
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J. Murray
Officer — President & CEO · Director
Period of report
Jun 16, 2016
Accepted (ET)
Jun 20, 2016 · 8:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Jun 16, 2016 | X | 5,000 | $2.5688 | A | 289,389 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantsF2,F1 | $2.5688 | Jun 16, 2016 | X | 5,000 | D | Jun 16, 2011 | Jun 16, 2016 | Common shares | 5,000 | 0 | D |
Explanation of responses
- F1Exercise price of Cdn$3.35 converted into U.S. dollars using the noon Bank of Canada exchange rate on June 16, 2016 of Cdn$1.3041=US$1.00.
- F2The warrants were purchased as part of a private placement unit offering for Cdn$2.85 per unit, each unit consisting of one common shares and one-half of one common share purchase warrant exercisable at Cdn$3.35 for five years.